PURPOSE: Some studies have reported reduced risks of advanced, but not early, prostate cancer among statin users, and one study found a reduced risk only among statin users who had also used non-steroidal anti-inflammatory drugs (NSAIDs). We have previously reported no association between statin use and prostate cancer in our hospital-based Case Control Surveillance Study. The purpose of the present analyses was to update the findings by cancer stage and to evaluate the joint use of statins and NSAIDs. METHODS: Cases were 1367 men with prostate cancer and controls were 2007 men with diagnoses unrelated to statin or NSAID use. We used multivariable logistic regression analyses to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for statin use compared with no use, and joint use of statin and NSAIDs compared with use of neither. RESULTS: The odds ratio among regular statin users was 1.1 (95%CI 0.9-1.5), and odds ratios were similar among early and late stage cancers. The odds ratio among joint statin and NSAID users was 1.1 (95%CI 0.7-1.6). CONCLUSION: The present results do not support a protective effect of statin use, or statin and NSAID use, on the risk of advanced prostate cancer. (c) 2010 John Wiley & Sons, Ltd.
PURPOSE: Some studies have reported reduced risks of advanced, but not early, prostate cancer among statin users, and one study found a reduced risk only among statin users who had also used non-steroidal anti-inflammatory drugs (NSAIDs). We have previously reported no association between statin use and prostate cancer in our hospital-based Case Control Surveillance Study. The purpose of the present analyses was to update the findings by cancer stage and to evaluate the joint use of statins and NSAIDs. METHODS: Cases were 1367 men with prostate cancer and controls were 2007 men with diagnoses unrelated to statin or NSAID use. We used multivariable logistic regression analyses to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for statin use compared with no use, and joint use of statin and NSAIDs compared with use of neither. RESULTS: The odds ratio among regular statin users was 1.1 (95%CI 0.9-1.5), and odds ratios were similar among early and late stage cancers. The odds ratio among joint statin and NSAID users was 1.1 (95%CI 0.7-1.6). CONCLUSION: The present results do not support a protective effect of statin use, or statin and NSAID use, on the risk of advanced prostate cancer. (c) 2010 John Wiley & Sons, Ltd.
Authors: Elizabeth A Platz; Michael F Leitzmann; Kala Visvanathan; Eric B Rimm; Meir J Stampfer; Walter C Willett; Edward Giovannucci Journal: J Natl Cancer Inst Date: 2006-12-20 Impact factor: 13.506
Authors: Ilir Agalliu; Claudia A Salinas; Philip D Hansten; Elaine A Ostrander; Janet L Stanford Journal: Am J Epidemiol Date: 2008-06-12 Impact factor: 4.897
Authors: Timo E Strandberg; Kalevi Pyörälä; Thomas J Cook; Lars Wilhelmsen; Ole Faergeman; Gudmundur Thorgeirsson; Terje R Pedersen; John Kjekshus Journal: Lancet Date: 2004 Aug 28-Sep 3 Impact factor: 79.321
Authors: Ian Ford; Heather Murray; Chris J Packard; James Shepherd; Peter W Macfarlane; Stuart M Cobbe Journal: N Engl J Med Date: 2007-10-11 Impact factor: 91.245
Authors: Gary D Friedman; E Dawn Flick; Natalia Udaltsova; James Chan; Charles P Quesenberry; Laurel A Habel Journal: Pharmacoepidemiol Drug Saf Date: 2008-01 Impact factor: 2.890
Authors: Eric J Jacobs; Carmen Rodriguez; Elizabeth B Bain; Yiting Wang; Michael J Thun; Eugenia E Calle Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-10-30 Impact factor: 4.254
Authors: Mahmoud A Alfaqih; Erik R Nelson; Wen Liu; Rachid Safi; Jeffery S Jasper; Everardo Macias; Joseph Geradts; J Will Thompson; Laura G Dubois; Michael R Freeman; Ching-Yi Chang; Jen-Tsan Chi; Donald P McDonnell; Stephen J Freedland Journal: Cancer Res Date: 2017-01-27 Impact factor: 12.701
Authors: Mahmoud A Alfaqih; Emma H Allott; Robert J Hamilton; Michael R Freeman; Stephen J Freedland Journal: Nat Rev Urol Date: 2016-10-25 Impact factor: 14.432
Authors: Elizabeth A Platz; Catherine M Tangen; Phyllis J Goodman; Cathee Till; Howard L Parnes; William D Figg; Demetrius Albanes; Marian L Neuhouser; Eric A Klein; M Scott Lucia; Ian M Thompson; Alan R Kristal Journal: J Urol Date: 2014-02-08 Impact factor: 7.450
Authors: Fatma M Shebl; Ann W Hsing; Yikyung Park; Albert R Hollenbeck; Lisa W Chu; Tamra E Meyer; Jill Koshiol Journal: PLoS One Date: 2014-12-31 Impact factor: 3.240
Authors: Cleo Robinson; Helman Alfonso; Samantha Woo; Amy Walsh; Nola Olsen; Arthur W Musk; Bruce W S Robinson; Anna K Nowak; Richard A Lake Journal: PLoS One Date: 2014-08-05 Impact factor: 3.240